cmAngio® vs uOmnispace.MR
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to integrate cardiovascular risk assessment into routine mammography screenings for women. This AI software is ideal for automatically detecting Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing crucial insights into cardiovascular health without additional radiation or procedures.
View cmAngio® →Choose uOmnispace.MR if…
Choose uOmnispace.MR if you require comprehensive, AI-powered analysis of Magnetic Resonance (MR) images across diverse clinical applications, including detailed brain, breast, and cardiac studies. This tool is best suited for advanced post-processing, AI-driven segmentation (e.g., cardiac ventricular), and functional analysis such as perfusion or dynamic studies, to enhance diagnostic precision.
View uOmnispace.MR →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | uOmnispace.MR |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact for pricing |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Software-only medical device; can run standalone or integrated with other cleared applications on standard off-the-shelf PCs; supports remote multi-user access on a network. The broader uOmnispace platform is available as SaaS, on-premise, or hybrid. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A (cmAngiou00ae) emphasizes a 'quick and easy installation (less than an hour)' and compatibility with any DICOM-compliant viewer, suggesting seamless integration into existing radiology workflows. Its focus on providing a '2-for-1' exam by leveraging existing mammography infrastructure for a new insight enhances its practical usability for clinicians. While Tool B offers flexible deployment, Tool A's direct integration into a familiar workflow for a specific, impactful purpose gives it an edge in immediate user adoption.
Clinical Value
cmAngio®Tool A (cmAngiou00ae) offers a highly innovative clinical value by detecting Breast Arterial Calcifications (BAC) on routine mammograms, providing insights into cardiovascular health and aiding early risk assessment without additional radiation or procedures. This repurposes existing data for a new, critical health insight, which has been shown to correlate with increased cardiovascular disease risk and mortality. Tool B provides comprehensive MR image analysis, but Tool A's novel application to an existing screening for a new preventative health marker is more impactful.
Pricing & Value
uOmnispace.MRBoth tools require direct contact for pricing, lacking public transparency. However, Tool B (uOmnispace.MR) explicitly offers 'Software Upgrades for Lifeu2122' at no additional charge, including installation and clinical applications, which provides significant long-term value and cost predictability for enterprises. While Tool A mentions 'limited-time offers for no-cost implementation and service,' Tool B's commitment to lifetime software upgrades represents a more substantial and enduring value proposition.
Enterprise Readiness
uOmnispace.MRBoth tools are FDA-cleared and HIPAA-compliant. However, Tool B (uOmnispace.MR) explicitly states it 'has_baa': '1', whereas Tool A requires contacting the vendor for BAA details. More significantly, Tool B offers highly flexible deployment options including standalone, integrated, SaaS, on-premise, or hybrid, and supports remote multi-user access, catering to diverse enterprise IT infrastructures. This comprehensive flexibility and explicit BAA status make Tool B more robustly enterprise-ready.
Innovation
cmAngio®Tool A (cmAngiou00ae) demonstrates superior innovation by applying AI to routine mammograms for the novel purpose of detecting Breast Arterial Calcifications (BAC) to assess cardiovascular risk. This '2-for-1' approach leverages existing data to provide new, critical health insights, making it the 'firstu2014and currently onlyu2014FDA-cleared AI software' for this specific application. While Tool B offers advanced AI for MR analysis, its applications are more incremental advancements within established imaging modalities.
Support & Docs
uOmnispace.MRTool B (uOmnispace.MR) is backed by United Imaging Healthcare, which offers a comprehensive support ecosystem including various on-site and headquarters training programs, an online document library, and 24/7 specialized remote monitoring. Tool A's information primarily focuses on quick installation, with no explicit details on ongoing support or documentation beyond general company statements. Therefore, Tool B clearly provides more robust and detailed support and documentation resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | uOmnispace.MR |
|---|---|---|
| Product Name | cmAngiou00ae | uOmnispace.MR |
| Company | CureMetrix | Shanghai United Imaging Healthcare Co., Ltd. |
| Primary Function | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI-powered software for comprehensive magnetic resonance (MR) image analysis, supporting diverse clinical applications including brain, breast, and cardiac imaging with advanced post-processing tools and AI-driven segmentation. |
| Supported Imaging Modalities | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | MR images (brain, breast, cardiac imaging) |
| Key AI Functionality | AI-based detection of Breast Arterial Calcifications (BAC) | AI-driven cardiac ventricular segmentation; AI-driven segmentation |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and uOmnispace.MR.